...
首页> 外文期刊>Molecular BioSystems >An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells
【24h】

An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells

机译:整合的比较性磷酸蛋白质组学和生物信息学方法揭示了在表达EGFRvIII的胶质母细胞瘤细胞中上调的新型MPM-2基序

获取原文
获取原文并翻译 | 示例
           

摘要

Glioblastoma (GBM, WHO grade IV) is an aggressively proliferative and invasive brain tumor that carries a poor clinical prognosis with a median survival of 9 to 12 months. In a prior phosphoproteomic study performed in the U87MG glioblastoma cell line, we identified tyrosine phosphorylation events that are regulated as a result of titrating EGFRvIII, a constitutively active mutant of the epidermal growth factor receptor (EGFR) associated with poor prognosis in GBM patients. In the present study, we have used the phosphoserine/phosphothreonine-specific antibody MPM-2 (mitotic protein monoclonal #2) to quantify serine/threonine phosphorylation events in the same cell lines. By employing a bioinformatic tool to identify amino acid sequence motifs regulated in response to increasing oncogene levels, a set of previously undescribed MPM-2 epitope sequence motifs orthogonal to the canonical "pS/pT-P" motif was identified. These motifs contain acidic amino acids in combinations of the -5, -2, + 1, +3, and +5 positions relative to the phosphorylated amino acid. Phosphopeptides containing these motifs are upregulated in cells expressing EGFRvIII, raising the possibility of a general role for a previously unrecognized acidophilic kinase (e.g. casein kinase II (CK2)) in cell proliferation downstream of EGFR signaling.
机译:胶质母细胞瘤(GBM,WHO IV级)是一种侵袭性增生性和浸润性脑肿瘤,临床预后较差,中位生存期为9至12个月。在先前在U87MG胶质母细胞瘤细胞系中进行的磷酸化蛋白质组学研究中,我们确定了酪氨酸磷酸化事件是由于滴定EGFRvIII而调节的,EGFRvIII是表皮生长因子受体(EGFR)的组成型活性突变体,与GBM患者的预后不良相关。在本研究中,我们使用了磷酸丝氨酸/磷酸苏氨酸特异性抗体MPM-2(有丝分裂蛋白单克隆抗体#2)来定量同一细胞系中的丝氨酸/苏氨酸磷酸化事件。通过使用生物信息学工具来鉴定响应于增加的致癌基因水平而调节的氨基酸序列基序,鉴定了与规范的“ pS / pT-P”基序正交的一组先前未描述的MPM-2表位序列基序。这些基序包含相对于磷酸化氨基酸为-5,-2,+ 1,+ 3和+5位的酸性氨基酸。包含这些基序的磷酸肽在表达EGFRvIII的细胞中被上调,从而增加了先前无法识别的嗜酸激酶(例如酪蛋白激酶II(CK2))在EGFR信号下游的细胞增殖中发挥一般作用的可能性。

著录项

  • 来源
    《Molecular BioSystems》 |2009年第1期|59-67|共9页
  • 作者单位

    The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA;

    Dept. of Biological Engineering, MIT, Cambridge, MA, USA;

    Dept. of Biological Engineering, MIT, Cambridge, MA, USA;

    The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA Dept. of Biological Engineering, MIT, Cambridge, MA, USA;

    The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA Dept. of Biological Engineering, MIT, Cambridge, MA, USA;

    The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA Dept. of Biological Engineering, MIT, Cambridge, MA, USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号